Hood River Capital Management LLC Buys 98,892 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX)

Hood River Capital Management LLC increased its stake in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) by 6.7% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,572,929 shares of the biopharmaceutical company’s stock after acquiring an additional 98,892 shares during the quarter. Hood River Capital Management LLC owned approximately 1.02% of TG Therapeutics worth $27,982,000 at the end of the most recent quarter.

A number of other large investors have also bought and sold shares of TGTX. Norges Bank bought a new position in shares of TG Therapeutics during the 4th quarter worth about $18,362,000. Assenagon Asset Management S.A. acquired a new position in TG Therapeutics during the 2nd quarter worth approximately $8,698,000. Eventide Asset Management LLC bought a new position in TG Therapeutics in the fourth quarter worth approximately $7,506,000. Opaleye Management Inc. grew its stake in TG Therapeutics by 17.2% in the fourth quarter. Opaleye Management Inc. now owns 2,215,000 shares of the biopharmaceutical company’s stock valued at $37,832,000 after acquiring an additional 325,000 shares during the period. Finally, UBS Group AG grew its stake in TG Therapeutics by 67.2% in the fourth quarter. UBS Group AG now owns 564,836 shares of the biopharmaceutical company’s stock valued at $9,647,000 after acquiring an additional 226,971 shares during the period. 58.58% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

TGTX has been the topic of a number of recent research reports. The Goldman Sachs Group increased their target price on TG Therapeutics from $18.00 to $20.00 and gave the stock a “neutral” rating in a report on Wednesday, August 7th. B. Riley upped their price objective on shares of TG Therapeutics from $29.00 to $34.00 and gave the stock a “buy” rating in a report on Wednesday, August 7th. Finally, HC Wainwright reiterated a “buy” rating and set a $49.00 price objective on shares of TG Therapeutics in a report on Wednesday, September 18th. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $31.83.

TG Therapeutics Trading Down 2.5 %

NASDAQ TGTX opened at $24.65 on Monday. The company has a current ratio of 3.58, a quick ratio of 2.83 and a debt-to-equity ratio of 0.58. The firm has a market capitalization of $3.81 billion, a P/E ratio of 107.17 and a beta of 2.21. The business has a fifty day simple moving average of $22.08 and a 200 day simple moving average of $18.35. TG Therapeutics, Inc. has a 12 month low of $6.46 and a 12 month high of $26.41.

TG Therapeutics (NASDAQ:TGTX) last released its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported $0.04 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.08. TG Therapeutics had a net margin of 27.60% and a return on equity of 57.73%. The company had revenue of $73.47 million for the quarter, compared to analyst estimates of $65.92 million. During the same period last year, the firm earned ($0.34) earnings per share. The firm’s revenue was up 357.0% on a year-over-year basis. On average, analysts predict that TG Therapeutics, Inc. will post 0.13 EPS for the current fiscal year.

TG Therapeutics Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.